Source disclosure: February 13, 2026
Sumitomo Pharma Co., Ltd. [4506.T]
TOKYO, Feb 13 (Pulse News Wire) – Sumitomo Pharma CO.,LTD. (4506.T) and RACTHERA Corp.
Submitted a manufacturing and marketing application for their non-self induced pluripotent stem cell-derived dopamine neuron precursor cells, known as Amsherpri, on August 05, 2025., the Ministry of Health, Labour and Welfare’s Pharmaceutical Affairs Council scheduled a meeting to review the product under its regenerative medical products committee. Amsherpri, also referred to as RaguneProCel, aims to improve off-time motor symptoms in patients with advanced Parkinson's disease.
The outcome of the upcoming deliberation will determine whether the therapy receives approval. Sumitomo Pharma stated that there would be no impact on the fiscal year ending March 2026 consolidated earnings should the application be denied.
Further updates will be communicated promptly if additional significant developments arise during the regulatory process.
AI-translated content. 🟢 Confidence: High See terms • Original filing